Literature DB >> 30706350

Psychotropic Medication Use for Adults with Autism Spectrum Disorder who Receive Services and Supports Through Adult Developmental Disability Services in the United States.

Amy Esler1, Amy Hewitt2, Jennifer Hall-Lande2, Sandra L Pettingell2, James Houseworth2.   

Abstract

Individuals with autism spectrum disorder (ASD) have higher rates of co-occurring diagnoses and use of psychotropic medication prescriptions than people with other developmental disabilities. Few studies have examined these trends in samples of people with intellectual and developmental disabilities (IDD) with and without ASD. Using a random sample of 11,947 adult IDD service users from 25 states, co-occurring diagnoses and psychotropic medication use were compared for those with and without ASD. Regardless of diagnosis, individuals with ASD had higher percentages of psychotropic medication use. Controlling for co-occurring condition, age, gender, and ID level, a diagnosis of ASD predicted number of medications used. Further research is needed to understand why individuals with ASD are prescribed more medication, more often, than similarly functioning groups of individuals without ASD.

Entities:  

Keywords:  ASD; Autism spectrum disorder; Community living; ID; Intellectual and developmental disabilities; National core indicators; Psychotropic medications

Mesh:

Substances:

Year:  2019        PMID: 30706350     DOI: 10.1007/s10803-019-03903-7

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  4 in total

1.  Testing a Wellness Indicators Measure for People with Intellectual and Developmental Disabilitiesa.

Authors:  Matthew Bogenschutz; Michael Broda; Sarah Lineberry; Parthenia Dinora; Seb Prohn
Journal:  Dev Disabil Netw J       Date:  2021

2.  College as a Developmental Context for Emerging Adulthood in Autism: A Systematic Review of What We Know and Where We Go from Here.

Authors:  Chaia Flegenheimer; K Suzanne Scherf
Journal:  J Autism Dev Disord       Date:  2021-05-31

3.  Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review.

Authors:  Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2020-11-23       Impact factor: 5.321

Review 4.  Gender Trends in Psychotropic Medication Use in Autism.

Authors:  Christopher R Huber; Zachary Fanaro; Varun Soti
Journal:  Cureus       Date:  2022-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.